<DOC>
	<DOCNO>NCT01265927</DOCNO>
	<brief_summary>A study evaluate safety biologic effect give GRN163L combination trastuzumab patient diagnose HER2+ metastatic breast cancer resistant therapy trastuzumab .</brief_summary>
	<brief_title>A Study Inhibiting Telomerase Reverse Trastuzumab Resistance HER2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Males females 18 year old time consent . 2 . ECOG performance status 02 within 21 day study registration . 3 . Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease . NOTE : locally recurrent disease must amenable surgery radiation curative intent . 4 . Measurable evaluable disease accord RECIST v1.1 within 35 day prior study registration . 5 . Disease must amenable biopsy ( imageguided via direct visualization superficial lesion ) minimal risk patient . NOTE : Patients disease limit lung and/or pleura exclude . 6 . Disease must HER2+ define IHC 3+ FISH ratio &gt; 2.0 . 7 . Resistant trastuzumab define ( 1 ) progression within 12 month complete adjuvant/neoadjuvant trastuzumab ( 2 ) progression trastuzumab administer metastatic disease . 8 . Prior treatment lapatinib investigational HER2 target therapy allow require . There limit number regimen prior antiHER2 therapy patient receive . 9 . LVEF ≥ Lower Limit Normal base MUGA ECHO within 35 day prior study registration 10 . Females childbearing potential male must willing use effective method contraception time consent sign 6 month treatment discontinuation . Methods contraception include hormonal birth control ( oral contraceptive , patch , injection , vaginal ring implant ) , two barrier method birth control , abstinence and/or method determine treat physician . 11 . Females childbearing potential must negative pregnancy test within 14 day prior registration protocol therapy . NOTE : Females consider child bear potential unless surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( &gt; 12 month since last menses ) . Laboratory value must obtain within 21 day study registration : 12 . Absolute neutrophil count ( ANC ) ≥ 1.5 K/mm3 13 . Platelets ≥ 100 K/mm3 14 . Hemoglobin ( Hgb ) ≥ 9.0 g/dL ( may transfuse ) 15 . Serum creatinine &lt; 3.0 mg/dL 16 . Total Bilirubin ≤ 1.5 x ULN 17 . AST/SGOT ≤ 2.5 x ULN . If liver metastasis present , AST ≤ 5 x ULN 18 . ALT , SGPT ≤ 2.5 x ULN . If liver metastasis present , ALT ≤ 5 x ULN 19 . No Investigational therapy within 4 week study registration 20 . No hormonal therapy within 2 week study registration 21 . No cytotoxic chemotherapy within 2 week study registration . 22 . No prior treatment GRN163L 23 . No prior history severe reaction trastuzumab , determine treat physician . 24 . No history clinically significant cardiac dysfunction , include : Current uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) , unstable angina History symptomatic CHF ( Grade &gt; 3 NCI CTCAE Class &gt; II NYHA criterion [ see Appendix IV ] ) serious cardiac arrhythmia require treatment within 12 month study registration , exception atrial fibrillation paroxysmal supraventricular tachycardia History myocardial infarction within 6 month study registration 25 . No history cerebrovascular accident within 12 month study registration 26 . No active CNS metastasis . Patients previously treat CNS metastasis require chronic steroid anticonvulsant eligible . 27 . Prior radiation therapy must involve &gt; 25 % bone marrow due potential myelosuppression GRN163L . See bone marrow chart Appendix III NOTE : Radiation therapy within 2 week study registration allow . 28 . Females must breastfeed . 29 . No clinically significant active infection , determine treat physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Genes , HER-2</keyword>
	<keyword>Genes , HER2</keyword>
</DOC>